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Abstract: Longitudinal opioid prescription use is unknown among
HIV-infected patients. Group-based trajectory modeling followed by
multinomial logistic regression was used to identify distinct trajecto-
ries and their association with baseline characteristics among 1239
HIV-infected UNC CFAR HIV Clinical Cohort participants, 2000–
2014. Three trajectories were identified: (1) 72% never/sporadic
opioid use (referent group), (2) 11% episodic use (associated with
female sex, depression, drug-related diagnoses, antiretroviral therapy
use, and undetectable HIV RNA), and (3) 16% chronic use (associated
with older age, female sex, and mental health diagnoses). Overall,
opioid prescription decreased substantially with longer time in HIV
care among both episodic and chronic users.
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INTRODUCTION
Both therapeutic use and misuse of opioids have
escalated over the last few decades in the United States.1
The number of persons receiving an opioid prescription more
than doubled in the Veterans Aging Cohort Study-Virtual
Cohort between 1999 and 2010, among both HIV-infected
and uninfected participants.2 HIV-infected patients may be
prescribed opioids twice as often as HIV-uninfected persons.3
Although guidelines for opioid prescription have been issued
by the Centers for Disease Control and Prevention,4
guideline-concordant care is inconsistent among HIV-
infected patients.5 Although the increased risks of misuse,6
mortality,7,8 and other adverse health outcomes9–11 associated
with opioid use have been established, longitudinal opioid use
has not been well defined and little is known about changes in
HIV-infected individuals’ use over time. The objectives of
this exploratory study were to identify patterns of longitudinal
opioid prescription use and to assess their association with
patient characteristics.
METHODS
The University of North Carolina Center for AIDS
Research HIV Clinical Cohort (UCHCC) is an ongoing
prospective cohort of all patients receiving primary HIV care
at the University of North Carolina Hospitals. The UCHCC
study and procedures have been previously described, and the
cohort is representative of HIV-infected patients in care in
North Carolina.12 The analytic sample consisted of all
UCHCC participants in care (ie, at least 1 clinic visit or
CD4 cell count/HIV viral load test per year) for a minimum of
5 years between 2000 and 2014. Baseline was defined as the
first year in care at UNC hospitals in or after 2000.
Each year, participants were categorized based on their
opioid prescription receipt. The opioids considered were
codeine, hydrocodone, hydromorphone, morphine, oxyco-
done, oxymorphone, propoxyphene, tramadol, and fentanyl.
Only medications with pain management indication were
included (eg, cough suppressants containing codeine were
excluded). Methadone was excluded (n = 13) because the
indication was unknown (eg, substitution therapy or chronic
pain). Data on prescription medication use during each
calendar year as well as sociodemographic and clinical
characteristics were obtained from electronic medical records
and supplemented by standardized medical record reviews.
No information on the specific date, dose, and duration of
opioid prescription was available.
Group-based trajectory models,13 a longitudinal exten-
sion of latent-class analysis, were used to map the course of
opioid use over time and identify clusters of individuals
following similar trajectories. Models with 1–6 groups were
fitted successively and compared to select the optimal number
of trajectories. Model selection was based on model fit,
adequacy, and interpretability. Fit was assessed with the
Akaike information criterion and the Bayesian information
criterion. Adequacy was assessed with correspondence
between the estimated probability of group membership
and the proportion assigned to the group, and an average
posterior probability of group membership $0.70.14 Group
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membership was assigned based on each patient’s highest
posterior probability of belonging to a specific group.
Predicted probabilities of opioid use within each
trajectory group were plotted against the number of years in
care. Group membership was used as the outcome in
a multivariate multinomial logistic regression to assess its
relationship with sociodemographic and clinical character-
istics at baseline (ie, first year of HIV care at UNC in or after
2000). Selected characteristics included in a fully adjusted
model were diagnoses of chronic pain, alcohol use– and any
drug use–related diagnoses, depression, mental illness
(excluding depression), sex, race, age, antiretroviral therapy
(ART) use, HIV RNA suppression (HIV RNA ,50 copies/
mL throughout the year), and CD4 cell count (lowest value
for the year).
RESULTS
Overall 1239 HIV-infected patients had at least 5 years
of HIV care follow-up between 2000 and 2014. The median
calendar year of entry to the cohort was 2005 [interquartile
range (IQR), 2002–2008], and the median years contributed
to follow-up was 9 (IQR, 7–12), with a total of 11,764
person-years of follow-up. Patients were predominantly black
(60%), male (70%), with a median age of 39 years at baseline
(Table 1). At baseline, the median CD4 cell count was 306
cells per cubic millimeter, 48% used ART, and 14% were
virologically suppressed.
The 3-group model provided the best fit to the data. The
first group consisted of patients with never/sporadic opioid
use, with median 7% of follow-up years with opioid use
(IQR, 0%–17%). The second group consisted of patients with
episodic use who received at least 1 opioid prescription in
a minimum of 2 consecutive years, with median 30% of
follow-up years with opioid use (IQR, 25%–38%). The third
group consisted of patients with chronic use who received
opioid prescriptions for at least half the years in care, with
median 63% of follow-up years with opioid use (IQR, 54%–
80%). This model provided the closest correspondence
between the estimated probability of group membership and
the proportion assigned to each group, with values of
0.64/0.72, 0.19/0.11, and 0.16/0.16 for the never/sporadic,
episodic, and chronic use groups, respectively. The mean
posterior probability was good in each group at 0.85, 0.75,
and 0.88, for the never/sporadic, episodic, and chronic use
groups, respectively. Only a marginal improvement in model
fit (Akaike information criterion and Bayesian information
criterion) was observed in models with more than 3 groups.
Finally, the 3-group model decreased heterogeneity within
groups and increased heterogeneity between groups.
With this model, 898 patients (72%) were assigned to
the never/sporadic, 141 (11%) to the episodic, and 200 (16%)
to the chronic use group. The estimated predicted probability
of opioid use decreased at first then stabilized over time
among never/sporadic users, increased and then decreased
over time among episodic users, whereas the probability of
use was stable and then decreased with time among chronic
opioid users (Fig. 1). Among the never/sporadic users, the
predicted probabilities of opioid use at 1, 5, 10, and 15 years
of care, respectively, were 16% [95% confidence interval
(CI): 13 to 18], 8% (7 to 10), 8% (6 to 10), and 6% (2 to 11).
Among the episodic users, these probabilities were 7% (0 to
15), 22% (14 to 30), 51% (41 to 62), and 14% (2 to 25), and
among the chronic users, 64% (55 to 73), 69% (64 to 74),
60% (54 to 66), and 35% (15 to 55) (estimated flexibly with
statistically significant quadratic or cubic functions).
TABLE 1. Baseline Patient Characteristics and Associations With Longitudinal Opioid Use Using Never/Sporadic Use (n = 898,
72%) as the Referent Outcome in a Multivariate Multinomial Logistic Regression Model
Baseline Characteristics,
N (%) or Median (IQR)
Opioid Use Group
Episodic Use Adjusted
Odds Ratio (95% CI)
Chronic Use Adjusted
Odds Ratio (95% CI)
N (%) 1239 (100) 141 (11) 200 (16)
Female sex 372 (30) 1.82 (1.17 to 2.83)* 2.86 (1.71 to 4.79)*
Race
White 366 (30) Ref. Ref.
Black 739 (60) 1.45 (0.89 to 2.34) 0.90 (0.52 to 1.54)
Other 134 (11) 0.88 (0.40 to 1.94) 0.49 (0.16 to 1.48)
Age, yrs 39 (24–46) 1.19 (0.98 to 1.46) 1.37 (1.08 to 1.75)*
CD4 cell count, cells/mm3 306 (144–499) 0.99 (0.92 to 1.08) 0.93 (0.84 to 1.03)
ART use 589 (48) 1.74 (1.12 to 2.68)* 1.39 (0.80 to 2.42)
Suppressed HIV RNA† 175 (14) 3.28 (1.48 to 7.26)* 1.24 (0.58 to 2.69)
Chronic pain‡ 25 (2) 1.44 (0.32 to 6.48) 2.84 (0.73 to 11.00)
Alcohol-related diagnosis‡ 69 (6) 1.15 (0.43 to 3.09) 1.98 (0.72 to 5.50)
Drug-related diagnosis‡ 157 (13) 2.18 (1.11 to 4.28)* 1.74 (0.80 to 3.78)
Depression‡ 150 (12) 2.89 (1.42 to 5.87)* 1.55 (0.69 to 3.50)
Mental illness‡ 85 (7) 0.88 (0.23 to 3.38) 5.60 (2.55 to 12.27)*
*P value ,0.05.
†HIV viral load ,50 copies per milliliter.
‡The presence of a physician diagnosis of chronic pain, alcohol use disorder, drug use disorder, depression, or mental illness excluding depression and recorded in a patient’s medical records.
a drug-related or depression diagnosis at baseline were
associated with episodic opioid use. Older age and a mental
health diagnosis other than depression at baseline were
associated with chronic opioid use.
Most participants rarely received opioid prescription,
which was, therefore, likely used for short-term treatment of
acute pain (eg, after an illness, injury, or surgery). Although
estimates of chronic pain prevalence in HIV-infected popula-
tions range from 53% to 90%,15,16 only 16% received chronic
opioid treatment in this cohort. We were unable to assess receipt
of alternate pain management. Chronic use group membership
was associated with mental illness other than depression, female
sex, and older age. Female sex3,17 and mental illnesses such as
anxiety and posttraumatic stress disorder have previously been
associated with opioid use among HIV-infected individu-
als,2,17,18 although individuals with schizophrenia are less likely
to receive opioids.2 Older age has been associated with both an
increase2,3,18 and a decrease in the risk of opioid use.17 Drug-
related diagnoses were associated with the episodic use group in
this study. Both substance use disorders and history of drug use
have been associated with long-term, daily, or high-dose opioid
use in some studies of HIV-infected persons.2,3,19 However,
other studies have found either no association with any or
chronic opioid prescription17,18 or a protective association for
any opioid receipt among HIV-infected persons.2
Only 9% of the study population were episodic users.
We were unable to assess whether these patients were
receiving opioids for ongoing comorbidities, or whether they
had ongoing chronic pain that was alternately being managed
with different strategies. It is also possible that some of these
patients used opioids prescribed by other providers without
the knowledge of their primary HIV care provider.
Although pain-related diagnoses have previously been
associated with opioid use,2,17,18 a baseline chronic pain
FIGURE 1. Probability of longitudinal
opioid use among HIV-infected patients
with never/sporadic, episodic, and
chronic opioid use estimated using
a group-based trajectory model.
A number of baseline characteristics were associated 
with longitudinal opioid use in a multivariate multinomial 
logistic regression model (Table 1). Compared with never/
sporadic users, episodic users were more likely to be female 
(odds ratio, 1.82, 95% CI: 1.17 to 2.83), depressed (2.89, 1.42 
to 5.87), have a drug-related diagnosis (2.18, 1.11 to 4.28), 
use ART (1.74, 1.12 to 2.68), and have suppressed HIV RNA 
(3.28, 1.48 to 7.26). Chronic users were more likely to be 
female (2.86, 1.71 to 4.79), be older (1.37 per 10 years, 1.08 
to 1.75), and have a mental illness (5.60, 2.55 to 12.27).
DISCUSSIONS
To our knowledge, this is the first investigation of 
longitudinal opioid use among HIV-infected patients receiv-
ing HIV care. We identified 3 distinct patterns of opioid use 
over time, including the most common of never/sporadic use, 
followed by chronic and episodic use. The probability of 
using opioids changed over time among both episodic and 
chronic users, with eventual decreases in probability of opioid 
use with longer time in care in both groups. Decreasing 
opioid use may be in part related to overall decreases in 
opioid prescription among this clinical population in more 
recent calendar years or to regression to the mean. This trend 
could also be explained by a shift toward earlier ART 
initiation in more recent years, potentially resulting in fewer 
patients with comorbid conditions necessitating pain man-
agement or better control of underlying comorbidities result-
ing from longer engagement in care, as well as, greater 
emphasis placed on the implementation of existing opioid 
agreements in the clinic starting in 2012.
The only factor associated with both episodic and 
chronic use, compared with never/sporadic use, was female 
sex. In addition, ART use, HIV RNA suppression, and
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diagnosis was not associated with specific trajectories of opioid 
use in this study. However, only 2% of patients had a chronic 
pain diagnosis at baseline, which could explain the elevated point 
estimates, but wide CIs observed. This low prevalence is likely 
an underestimation in this study, given prior estimates,15,16 and 
could result in part from the use of chart reviews rather than 
patient self-report of chronic pain. In addition, we only included 
a chronic pain diagnosis at the beginning of follow-up, rather 
than including all chronic pain diagnoses occurring during 
follow-up. Although studies have shown that white HIV-
infected persons are more likely to receive long-term and high-
dose opioid prescriptions in very large cohorts of HIV-infected 
persons,2,3,17 no such association was identified for opioid 
prescription trajectories in this study or with daily or chronic 
opioid prescription in other smaller HIV cohorts.18,19 Reduced 
power is, therefore, a possible explanation for this discrepancy.
The UCHCC is a large cohort representative of the HIV-
infected population in North Carolina, which relies on electronic 
records and standardized health record reviews, resulting in rich 
data on HIV and other comorbidities. However, opioid pre-
scription practices may vary across the United States, and these 
results may not be generalizable to all regions. Limited socio-
demographic and behavioral information was available. Alcohol 
and drug use–related diagnoses in the clinical record were 
included, although these diagnoses likely underestimate true 
prevalence. Limited information on opioid prescription was 
available; only yearly opioid use could be assessed, without 
information on the dose, reason for prescription, or prescription 
receipt from another source. In addition, this study focused on 
prescription receipt, and no inference can be made on actual use 
or misuse of these prescriptions.
Censoring of person-time could have affected grouping 
in group-based trajectory models. Follow-up time was cen-
sored administratively on January 1, 2015 and when a patient 
did not have a visit for over 1 year (loss to follow-up). The 
absence of information on opioid use after censoring can result 
in grouping misclassification. To minimize such misclassifica-
tion and to ensure that sufficient data were available to inform 
the trajectory of opioid use over time, the analytic sample was 
limited to patients with a minimum of 5 years in care.
This first study of patterns of opioid use over time in 
a representative cohort of HIV-infected persons engaged in 
clinical care identified 3 distinct trajectories: never/sporadic, 
episodic, and chronic use. A notable group of patients used 
opioids chronically and episodically, although the overall 
probabilities of use decreased with longer time in HIV care. 
Members of the chronic use group were more likely to be 
older, female, and to be diagnosed with mental illness. These 
findings highlight the need to further identify pharmacologic 
and nonpharmacologic treatments for chronic pain among 
HIV-infected patients, targeted toward vulnerable groups 
such as women and patients with mental illness.
